nodes	percent_of_prediction	percent_of_DWPC	metapath
Epoprostenol—PTGIR—Endothelin Pathways—COX2—peripheral nervous system neoplasm	0.00698	0.0883	CbGpPWpGaD
Epoprostenol—PTGIR—Prostacyclin signalling through prostacyclin receptor—GNAS—peripheral nervous system neoplasm	0.00462	0.0584	CbGpPWpGaD
Epoprostenol—PTGIR—Endothelin Pathways—GNAS—peripheral nervous system neoplasm	0.00297	0.0376	CbGpPWpGaD
Epoprostenol—PTGIS—Defective AMN causes hereditary megaloblastic anemia 1—SLC2A1—peripheral nervous system neoplasm	0.00232	0.0294	CbGpPWpGaD
Epoprostenol—PTGIR—G alpha (s) signalling events—VIP—peripheral nervous system neoplasm	0.00199	0.0251	CbGpPWpGaD
Epoprostenol—PTGER1—G alpha (q) signalling events—NTS—peripheral nervous system neoplasm	0.00189	0.0239	CbGpPWpGaD
Epoprostenol—PTGER1—Gastrin-CREB signalling pathway via PKC and MAPK—NTS—peripheral nervous system neoplasm	0.00169	0.0214	CbGpPWpGaD
Epoprostenol—PTGIR—Platelet homeostasis—GNAS—peripheral nervous system neoplasm	0.00149	0.0189	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism of lipids and lipoproteins—HSD17B12—peripheral nervous system neoplasm	0.00146	0.0185	CbGpPWpGaD
Epoprostenol—P2RY12—Class A/1 (Rhodopsin-like receptors)—NTS—peripheral nervous system neoplasm	0.00136	0.0172	CbGpPWpGaD
Epoprostenol—PTGIR—Class A/1 (Rhodopsin-like receptors)—NTS—peripheral nervous system neoplasm	0.00125	0.0158	CbGpPWpGaD
Epoprostenol—PTGER1—Class A/1 (Rhodopsin-like receptors)—NTS—peripheral nervous system neoplasm	0.00125	0.0158	CbGpPWpGaD
Epoprostenol—PTGIR—Platelet homeostasis—PTPN11—peripheral nervous system neoplasm	0.00104	0.0131	CbGpPWpGaD
Epoprostenol—P2RY12—GPCR ligand binding—NTS—peripheral nervous system neoplasm	0.00103	0.0131	CbGpPWpGaD
Epoprostenol—PTGIR—G alpha (s) signalling events—GNAS—peripheral nervous system neoplasm	0.00103	0.013	CbGpPWpGaD
Epoprostenol—P2RY12—GPCR ligand binding—CD55—peripheral nervous system neoplasm	0.000992	0.0125	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—PPIP5K2—peripheral nervous system neoplasm	0.000966	0.0122	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR ligand binding—NTS—peripheral nervous system neoplasm	0.000952	0.012	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR ligand binding—NTS—peripheral nervous system neoplasm	0.000952	0.012	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR ligand binding—CD55—peripheral nervous system neoplasm	0.000913	0.0115	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR ligand binding—CD55—peripheral nervous system neoplasm	0.000913	0.0115	CbGpPWpGaD
Epoprostenol—PTGER1—G alpha (q) signalling events—KNG1—peripheral nervous system neoplasm	0.000848	0.0107	CbGpPWpGaD
Epoprostenol—P2RY12—Platelet activation, signaling and aggregation—KNG1—peripheral nervous system neoplasm	0.000807	0.0102	CbGpPWpGaD
Epoprostenol—P2RY12—G alpha (i) signalling events—KNG1—peripheral nervous system neoplasm	0.000768	0.00971	CbGpPWpGaD
Epoprostenol—PTGER1—Gastrin-CREB signalling pathway via PKC and MAPK—KNG1—peripheral nervous system neoplasm	0.000759	0.0096	CbGpPWpGaD
Epoprostenol—Hyperhidrosis—Cisplatin—peripheral nervous system neoplasm	0.000677	0.000735	CcSEcCtD
Epoprostenol—Rash—Melphalan—peripheral nervous system neoplasm	0.000675	0.000733	CcSEcCtD
Epoprostenol—Dermatitis—Melphalan—peripheral nervous system neoplasm	0.000674	0.000732	CcSEcCtD
Epoprostenol—P2RY12—Platelet activation, signaling and aggregation—HGF—peripheral nervous system neoplasm	0.000672	0.0085	CbGpPWpGaD
Epoprostenol—Gastrointestinal pain—Alitretinoin—peripheral nervous system neoplasm	0.000672	0.00073	CcSEcCtD
Epoprostenol—P2RY12—G alpha (i) signalling events—GNAS—peripheral nervous system neoplasm	0.000671	0.00849	CbGpPWpGaD
Epoprostenol—Chest pain—Etoposide—peripheral nervous system neoplasm	0.000669	0.000726	CcSEcCtD
Epoprostenol—Orthostatic hypotension—Epirubicin—peripheral nervous system neoplasm	0.000668	0.000725	CcSEcCtD
Epoprostenol—Anorexia—Cisplatin—peripheral nervous system neoplasm	0.000667	0.000725	CcSEcCtD
Epoprostenol—Unspecified disorder of skin and subcutaneous tissue—Etoposide—peripheral nervous system neoplasm	0.000664	0.000721	CcSEcCtD
Epoprostenol—CYP2C9—Constitutive Androstane Receptor Pathway—ABCB1—peripheral nervous system neoplasm	0.00066	0.00834	CbGpPWpGaD
Epoprostenol—Hypotension—Cisplatin—peripheral nervous system neoplasm	0.000654	0.00071	CcSEcCtD
Epoprostenol—Hypersensitivity—Dactinomycin—peripheral nervous system neoplasm	0.000653	0.000709	CcSEcCtD
Epoprostenol—Urticaria—Alitretinoin—peripheral nervous system neoplasm	0.000653	0.000709	CcSEcCtD
Epoprostenol—PTGIS—Metabolism—HSD17B12—peripheral nervous system neoplasm	0.000652	0.00825	CbGpPWpGaD
Epoprostenol—Body temperature increased—Alitretinoin—peripheral nervous system neoplasm	0.00065	0.000705	CcSEcCtD
Epoprostenol—Abdominal pain—Alitretinoin—peripheral nervous system neoplasm	0.00065	0.000705	CcSEcCtD
Epoprostenol—Nausea—Topotecan—peripheral nervous system neoplasm	0.000649	0.000705	CcSEcCtD
Epoprostenol—Gastrointestinal pain—Vincristine—peripheral nervous system neoplasm	0.000647	0.000703	CcSEcCtD
Epoprostenol—Gastritis—Epirubicin—peripheral nervous system neoplasm	0.000647	0.000703	CcSEcCtD
Epoprostenol—Confusional state—Etoposide—peripheral nervous system neoplasm	0.000647	0.000702	CcSEcCtD
Epoprostenol—Nausea—Isotretinoin—peripheral nervous system neoplasm	0.000644	0.000699	CcSEcCtD
Epoprostenol—Nausea—Tretinoin—peripheral nervous system neoplasm	0.000644	0.000699	CcSEcCtD
Epoprostenol—Anaphylactic shock—Etoposide—peripheral nervous system neoplasm	0.000641	0.000696	CcSEcCtD
Epoprostenol—Musculoskeletal discomfort—Cisplatin—peripheral nervous system neoplasm	0.000638	0.000693	CcSEcCtD
Epoprostenol—Infection—Etoposide—peripheral nervous system neoplasm	0.000637	0.000692	CcSEcCtD
Epoprostenol—Abdominal distension—Epirubicin—peripheral nervous system neoplasm	0.000636	0.000691	CcSEcCtD
Epoprostenol—Asthenia—Dactinomycin—peripheral nervous system neoplasm	0.000636	0.00069	CcSEcCtD
Epoprostenol—Nausea—Melphalan—peripheral nervous system neoplasm	0.000636	0.00069	CcSEcCtD
Epoprostenol—Paraesthesia—Cisplatin—peripheral nervous system neoplasm	0.000629	0.000683	CcSEcCtD
Epoprostenol—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—peripheral nervous system neoplasm	0.000629	0.00795	CbGpPWpGaD
Epoprostenol—Thrombocytopenia—Etoposide—peripheral nervous system neoplasm	0.000628	0.000682	CcSEcCtD
Epoprostenol—Tachycardia—Etoposide—peripheral nervous system neoplasm	0.000626	0.00068	CcSEcCtD
Epoprostenol—Body temperature increased—Vincristine—peripheral nervous system neoplasm	0.000626	0.00068	CcSEcCtD
Epoprostenol—Abdominal pain—Vincristine—peripheral nervous system neoplasm	0.000626	0.00068	CcSEcCtD
Epoprostenol—Dyspnoea—Cisplatin—peripheral nervous system neoplasm	0.000624	0.000678	CcSEcCtD
Epoprostenol—Skin disorder—Etoposide—peripheral nervous system neoplasm	0.000623	0.000676	CcSEcCtD
Epoprostenol—Hyperhidrosis—Etoposide—peripheral nervous system neoplasm	0.00062	0.000673	CcSEcCtD
Epoprostenol—Orthostatic hypotension—Doxorubicin—peripheral nervous system neoplasm	0.000618	0.000671	CcSEcCtD
Epoprostenol—Anorexia—Etoposide—peripheral nervous system neoplasm	0.000611	0.000664	CcSEcCtD
Epoprostenol—P2RY12—Class A/1 (Rhodopsin-like receptors)—KNG1—peripheral nervous system neoplasm	0.000611	0.00772	CbGpPWpGaD
Epoprostenol—Decreased appetite—Cisplatin—peripheral nervous system neoplasm	0.000609	0.000661	CcSEcCtD
Epoprostenol—Diarrhoea—Dactinomycin—peripheral nervous system neoplasm	0.000606	0.000658	CcSEcCtD
Epoprostenol—Hypersensitivity—Alitretinoin—peripheral nervous system neoplasm	0.000605	0.000657	CcSEcCtD
Epoprostenol—Gastrointestinal disorder—Cisplatin—peripheral nervous system neoplasm	0.000604	0.000656	CcSEcCtD
Epoprostenol—Pancytopenia—Epirubicin—peripheral nervous system neoplasm	0.0006	0.000652	CcSEcCtD
Epoprostenol—Hypotension—Etoposide—peripheral nervous system neoplasm	0.000599	0.000651	CcSEcCtD
Epoprostenol—Gastritis—Doxorubicin—peripheral nervous system neoplasm	0.000599	0.00065	CcSEcCtD
Epoprostenol—Pain—Cisplatin—peripheral nervous system neoplasm	0.000599	0.00065	CcSEcCtD
Epoprostenol—Asthenia—Alitretinoin—peripheral nervous system neoplasm	0.00059	0.00064	CcSEcCtD
Epoprostenol—Abdominal distension—Doxorubicin—peripheral nervous system neoplasm	0.000589	0.000639	CcSEcCtD
Epoprostenol—P2RY12—GPCR downstream signaling—NTS—peripheral nervous system neoplasm	0.000585	0.00739	CbGpPWpGaD
Epoprostenol—Hypersensitivity—Vincristine—peripheral nervous system neoplasm	0.000583	0.000633	CcSEcCtD
Epoprostenol—Pruritus—Alitretinoin—peripheral nervous system neoplasm	0.000581	0.000631	CcSEcCtD
Epoprostenol—Paraesthesia—Etoposide—peripheral nervous system neoplasm	0.000576	0.000625	CcSEcCtD
Epoprostenol—Weight decreased—Epirubicin—peripheral nervous system neoplasm	0.000572	0.000621	CcSEcCtD
Epoprostenol—Dyspnoea—Etoposide—peripheral nervous system neoplasm	0.000572	0.000621	CcSEcCtD
Epoprostenol—Somnolence—Etoposide—peripheral nervous system neoplasm	0.00057	0.000619	CcSEcCtD
Epoprostenol—Asthenia—Vincristine—peripheral nervous system neoplasm	0.000568	0.000617	CcSEcCtD
Epoprostenol—Pneumonia—Epirubicin—peripheral nervous system neoplasm	0.000567	0.000616	CcSEcCtD
Epoprostenol—Infestation—Epirubicin—peripheral nervous system neoplasm	0.000564	0.000612	CcSEcCtD
Epoprostenol—Infestation NOS—Epirubicin—peripheral nervous system neoplasm	0.000564	0.000612	CcSEcCtD
Epoprostenol—Vomiting—Dactinomycin—peripheral nervous system neoplasm	0.000563	0.000612	CcSEcCtD
Epoprostenol—PTGIS—Disease—GNS—peripheral nervous system neoplasm	0.000563	0.00712	CbGpPWpGaD
Epoprostenol—Diarrhoea—Alitretinoin—peripheral nervous system neoplasm	0.000562	0.00061	CcSEcCtD
Epoprostenol—PTGER1—Class A/1 (Rhodopsin-like receptors)—KNG1—peripheral nervous system neoplasm	0.000562	0.00711	CbGpPWpGaD
Epoprostenol—PTGIR—Class A/1 (Rhodopsin-like receptors)—KNG1—peripheral nervous system neoplasm	0.000562	0.00711	CbGpPWpGaD
Epoprostenol—Rash—Dactinomycin—peripheral nervous system neoplasm	0.000559	0.000607	CcSEcCtD
Epoprostenol—Decreased appetite—Etoposide—peripheral nervous system neoplasm	0.000558	0.000605	CcSEcCtD
Epoprostenol—Pancytopenia—Doxorubicin—peripheral nervous system neoplasm	0.000556	0.000603	CcSEcCtD
Epoprostenol—Gastrointestinal disorder—Etoposide—peripheral nervous system neoplasm	0.000554	0.000601	CcSEcCtD
Epoprostenol—Body temperature increased—Cisplatin—peripheral nervous system neoplasm	0.000553	0.000601	CcSEcCtD
Epoprostenol—Fatigue—Etoposide—peripheral nervous system neoplasm	0.000553	0.0006	CcSEcCtD
Epoprostenol—Constipation—Etoposide—peripheral nervous system neoplasm	0.000548	0.000596	CcSEcCtD
Epoprostenol—Pain—Etoposide—peripheral nervous system neoplasm	0.000548	0.000596	CcSEcCtD
Epoprostenol—Urinary tract infection—Epirubicin—peripheral nervous system neoplasm	0.000548	0.000595	CcSEcCtD
Epoprostenol—Dizziness—Alitretinoin—peripheral nervous system neoplasm	0.000543	0.00059	CcSEcCtD
Epoprostenol—PTGIS—Metabolism of lipids and lipoproteins—BCHE—peripheral nervous system neoplasm	0.000542	0.00686	CbGpPWpGaD
Epoprostenol—Diarrhoea—Vincristine—peripheral nervous system neoplasm	0.000542	0.000588	CcSEcCtD
Epoprostenol—Sweating—Epirubicin—peripheral nervous system neoplasm	0.00054	0.000587	CcSEcCtD
Epoprostenol—PTGIR—GPCR downstream signaling—NTS—peripheral nervous system neoplasm	0.000538	0.0068	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR downstream signaling—NTS—peripheral nervous system neoplasm	0.000538	0.0068	CbGpPWpGaD
Epoprostenol—Haematuria—Epirubicin—peripheral nervous system neoplasm	0.000537	0.000584	CcSEcCtD
Epoprostenol—Epistaxis—Epirubicin—peripheral nervous system neoplasm	0.000532	0.000577	CcSEcCtD
Epoprostenol—P2RY12—Signaling by GPCR—NTS—peripheral nervous system neoplasm	0.000531	0.00671	CbGpPWpGaD
Epoprostenol—Weight decreased—Doxorubicin—peripheral nervous system neoplasm	0.000529	0.000575	CcSEcCtD
Epoprostenol—Sinusitis—Epirubicin—peripheral nervous system neoplasm	0.000529	0.000574	CcSEcCtD
Epoprostenol—Nausea—Dactinomycin—peripheral nervous system neoplasm	0.000526	0.000572	CcSEcCtD
Epoprostenol—PTGIR—Thromboxane A2 receptor signaling—AKT1—peripheral nervous system neoplasm	0.000525	0.00664	CbGpPWpGaD
Epoprostenol—Pneumonia—Doxorubicin—peripheral nervous system neoplasm	0.000525	0.00057	CcSEcCtD
Epoprostenol—Gastrointestinal pain—Etoposide—peripheral nervous system neoplasm	0.000524	0.000569	CcSEcCtD
Epoprostenol—Dizziness—Vincristine—peripheral nervous system neoplasm	0.000524	0.000569	CcSEcCtD
Epoprostenol—Vomiting—Alitretinoin—peripheral nervous system neoplasm	0.000522	0.000567	CcSEcCtD
Epoprostenol—Infestation NOS—Doxorubicin—peripheral nervous system neoplasm	0.000522	0.000566	CcSEcCtD
Epoprostenol—Infestation—Doxorubicin—peripheral nervous system neoplasm	0.000522	0.000566	CcSEcCtD
Epoprostenol—Rash—Alitretinoin—peripheral nervous system neoplasm	0.000518	0.000563	CcSEcCtD
Epoprostenol—Dermatitis—Alitretinoin—peripheral nervous system neoplasm	0.000518	0.000562	CcSEcCtD
Epoprostenol—Hypersensitivity—Cisplatin—peripheral nervous system neoplasm	0.000516	0.00056	CcSEcCtD
Epoprostenol—Bradycardia—Epirubicin—peripheral nervous system neoplasm	0.000515	0.000559	CcSEcCtD
Epoprostenol—Headache—Alitretinoin—peripheral nervous system neoplasm	0.000515	0.000559	CcSEcCtD
Epoprostenol—Urticaria—Etoposide—peripheral nervous system neoplasm	0.000509	0.000553	CcSEcCtD
Epoprostenol—P2RY12—Signaling by GPCR—CD55—peripheral nervous system neoplasm	0.000509	0.00644	CbGpPWpGaD
Epoprostenol—Haemoglobin—Epirubicin—peripheral nervous system neoplasm	0.000509	0.000552	CcSEcCtD
Epoprostenol—Rhinitis—Epirubicin—peripheral nervous system neoplasm	0.000507	0.000551	CcSEcCtD
Epoprostenol—Body temperature increased—Etoposide—peripheral nervous system neoplasm	0.000507	0.000551	CcSEcCtD
Epoprostenol—Abdominal pain—Etoposide—peripheral nervous system neoplasm	0.000507	0.000551	CcSEcCtD
Epoprostenol—Urinary tract infection—Doxorubicin—peripheral nervous system neoplasm	0.000507	0.000551	CcSEcCtD
Epoprostenol—Haemorrhage—Epirubicin—peripheral nervous system neoplasm	0.000506	0.000549	CcSEcCtD
Epoprostenol—Hypoaesthesia—Epirubicin—peripheral nervous system neoplasm	0.000503	0.000547	CcSEcCtD
Epoprostenol—Vomiting—Vincristine—peripheral nervous system neoplasm	0.000503	0.000547	CcSEcCtD
Epoprostenol—Asthenia—Cisplatin—peripheral nervous system neoplasm	0.000502	0.000545	CcSEcCtD
Epoprostenol—Pharyngitis—Epirubicin—peripheral nervous system neoplasm	0.000502	0.000545	CcSEcCtD
Epoprostenol—Sweating—Doxorubicin—peripheral nervous system neoplasm	0.0005	0.000543	CcSEcCtD
Epoprostenol—Rash—Vincristine—peripheral nervous system neoplasm	0.000499	0.000542	CcSEcCtD
Epoprostenol—Dermatitis—Vincristine—peripheral nervous system neoplasm	0.000499	0.000542	CcSEcCtD
Epoprostenol—Oedema peripheral—Epirubicin—peripheral nervous system neoplasm	0.000498	0.000541	CcSEcCtD
Epoprostenol—Haematuria—Doxorubicin—peripheral nervous system neoplasm	0.000497	0.00054	CcSEcCtD
Epoprostenol—Connective tissue disorder—Epirubicin—peripheral nervous system neoplasm	0.000497	0.00054	CcSEcCtD
Epoprostenol—Headache—Vincristine—peripheral nervous system neoplasm	0.000496	0.000539	CcSEcCtD
Epoprostenol—Epistaxis—Doxorubicin—peripheral nervous system neoplasm	0.000492	0.000534	CcSEcCtD
Epoprostenol—Sinusitis—Doxorubicin—peripheral nervous system neoplasm	0.000489	0.000531	CcSEcCtD
Epoprostenol—PTGER1—Signaling by GPCR—NTS—peripheral nervous system neoplasm	0.000489	0.00618	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—NTS—peripheral nervous system neoplasm	0.000489	0.00618	CbGpPWpGaD
Epoprostenol—Nausea—Alitretinoin—peripheral nervous system neoplasm	0.000488	0.00053	CcSEcCtD
Epoprostenol—Diarrhoea—Cisplatin—peripheral nervous system neoplasm	0.000479	0.00052	CcSEcCtD
Epoprostenol—Bradycardia—Doxorubicin—peripheral nervous system neoplasm	0.000477	0.000518	CcSEcCtD
Epoprostenol—Hypersensitivity—Etoposide—peripheral nervous system neoplasm	0.000473	0.000513	CcSEcCtD
Epoprostenol—PTGIS—Metabolism—GNS—peripheral nervous system neoplasm	0.000472	0.00596	CbGpPWpGaD
Epoprostenol—Haemoglobin—Doxorubicin—peripheral nervous system neoplasm	0.000471	0.000511	CcSEcCtD
Epoprostenol—Nausea—Vincristine—peripheral nervous system neoplasm	0.00047	0.000511	CcSEcCtD
Epoprostenol—Flushing—Epirubicin—peripheral nervous system neoplasm	0.00047	0.00051	CcSEcCtD
Epoprostenol—Cardiac disorder—Epirubicin—peripheral nervous system neoplasm	0.00047	0.00051	CcSEcCtD
Epoprostenol—Rhinitis—Doxorubicin—peripheral nervous system neoplasm	0.000469	0.00051	CcSEcCtD
Epoprostenol—PTGIR—Signaling by GPCR—CD55—peripheral nervous system neoplasm	0.000469	0.00592	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—CD55—peripheral nervous system neoplasm	0.000469	0.00592	CbGpPWpGaD
Epoprostenol—Haemorrhage—Doxorubicin—peripheral nervous system neoplasm	0.000468	0.000508	CcSEcCtD
Epoprostenol—Hypoaesthesia—Doxorubicin—peripheral nervous system neoplasm	0.000466	0.000506	CcSEcCtD
Epoprostenol—P2RY12—GPCR ligand binding—KNG1—peripheral nervous system neoplasm	0.000465	0.00588	CbGpPWpGaD
Epoprostenol—Pharyngitis—Doxorubicin—peripheral nervous system neoplasm	0.000465	0.000505	CcSEcCtD
Epoprostenol—Oedema peripheral—Doxorubicin—peripheral nervous system neoplasm	0.000461	0.000501	CcSEcCtD
Epoprostenol—PTGER1—Gastrin-CREB signalling pathway via PKC and MAPK—PTPN11—peripheral nervous system neoplasm	0.000461	0.00583	CbGpPWpGaD
Epoprostenol—Asthenia—Etoposide—peripheral nervous system neoplasm	0.00046	0.0005	CcSEcCtD
Epoprostenol—Connective tissue disorder—Doxorubicin—peripheral nervous system neoplasm	0.00046	0.0005	CcSEcCtD
Epoprostenol—Angiopathy—Epirubicin—peripheral nervous system neoplasm	0.000459	0.000499	CcSEcCtD
Epoprostenol—Mediastinal disorder—Epirubicin—peripheral nervous system neoplasm	0.000456	0.000495	CcSEcCtD
Epoprostenol—Chills—Epirubicin—peripheral nervous system neoplasm	0.000454	0.000493	CcSEcCtD
Epoprostenol—Pruritus—Etoposide—peripheral nervous system neoplasm	0.000454	0.000493	CcSEcCtD
Epoprostenol—PTGIS—Metabolism—NME1—peripheral nervous system neoplasm	0.000452	0.00572	CbGpPWpGaD
Epoprostenol—P2RY12—Hemostasis—IFNB1—peripheral nervous system neoplasm	0.000449	0.00567	CbGpPWpGaD
Epoprostenol—Vomiting—Cisplatin—peripheral nervous system neoplasm	0.000445	0.000483	CcSEcCtD
Epoprostenol—Mental disorder—Epirubicin—peripheral nervous system neoplasm	0.000443	0.000481	CcSEcCtD
Epoprostenol—P2RY12—GPCR downstream signaling—VIP—peripheral nervous system neoplasm	0.000443	0.0056	CbGpPWpGaD
Epoprostenol—Rash—Cisplatin—peripheral nervous system neoplasm	0.000441	0.000479	CcSEcCtD
Epoprostenol—Dermatitis—Cisplatin—peripheral nervous system neoplasm	0.000441	0.000479	CcSEcCtD
Epoprostenol—Diarrhoea—Etoposide—peripheral nervous system neoplasm	0.000439	0.000476	CcSEcCtD
Epoprostenol—PTGIS—Metabolism—COX2—peripheral nervous system neoplasm	0.000435	0.0055	CbGpPWpGaD
Epoprostenol—Cardiac disorder—Doxorubicin—peripheral nervous system neoplasm	0.000435	0.000472	CcSEcCtD
Epoprostenol—Flushing—Doxorubicin—peripheral nervous system neoplasm	0.000435	0.000472	CcSEcCtD
Epoprostenol—Flatulence—Epirubicin—peripheral nervous system neoplasm	0.000434	0.000471	CcSEcCtD
Epoprostenol—Tension—Epirubicin—peripheral nervous system neoplasm	0.000432	0.000469	CcSEcCtD
Epoprostenol—PTGER1—GPCR ligand binding—KNG1—peripheral nervous system neoplasm	0.000428	0.00541	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR ligand binding—KNG1—peripheral nervous system neoplasm	0.000428	0.00541	CbGpPWpGaD
Epoprostenol—Nervousness—Epirubicin—peripheral nervous system neoplasm	0.000428	0.000465	CcSEcCtD
Epoprostenol—Back pain—Epirubicin—peripheral nervous system neoplasm	0.000426	0.000463	CcSEcCtD
Epoprostenol—Angiopathy—Doxorubicin—peripheral nervous system neoplasm	0.000425	0.000461	CcSEcCtD
Epoprostenol—Dizziness—Etoposide—peripheral nervous system neoplasm	0.000424	0.000461	CcSEcCtD
Epoprostenol—Muscle spasms—Epirubicin—peripheral nervous system neoplasm	0.000424	0.00046	CcSEcCtD
Epoprostenol—Mediastinal disorder—Doxorubicin—peripheral nervous system neoplasm	0.000422	0.000458	CcSEcCtD
Epoprostenol—Chills—Doxorubicin—peripheral nervous system neoplasm	0.00042	0.000456	CcSEcCtD
Epoprostenol—Nausea—Cisplatin—peripheral nervous system neoplasm	0.000416	0.000452	CcSEcCtD
Epoprostenol—P2RY12—Hemostasis—KNG1—peripheral nervous system neoplasm	0.000416	0.00526	CbGpPWpGaD
Epoprostenol—PTGIR—Hemostasis—IFNB1—peripheral nervous system neoplasm	0.000413	0.00522	CbGpPWpGaD
Epoprostenol—Mental disorder—Doxorubicin—peripheral nervous system neoplasm	0.00041	0.000445	CcSEcCtD
Epoprostenol—PTGER1—GPCR downstream signaling—VIP—peripheral nervous system neoplasm	0.000408	0.00516	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR downstream signaling—VIP—peripheral nervous system neoplasm	0.000408	0.00516	CbGpPWpGaD
Epoprostenol—Vomiting—Etoposide—peripheral nervous system neoplasm	0.000408	0.000443	CcSEcCtD
Epoprostenol—Anaemia—Epirubicin—peripheral nervous system neoplasm	0.000407	0.000442	CcSEcCtD
Epoprostenol—P2RY12—GPCR ligand binding—GNAS—peripheral nervous system neoplasm	0.000407	0.00514	CbGpPWpGaD
Epoprostenol—Agitation—Epirubicin—peripheral nervous system neoplasm	0.000405	0.00044	CcSEcCtD
Epoprostenol—Rash—Etoposide—peripheral nervous system neoplasm	0.000404	0.000439	CcSEcCtD
Epoprostenol—Dermatitis—Etoposide—peripheral nervous system neoplasm	0.000404	0.000439	CcSEcCtD
Epoprostenol—P2RY12—Signaling by GPCR—VIP—peripheral nervous system neoplasm	0.000402	0.00509	CbGpPWpGaD
Epoprostenol—Headache—Etoposide—peripheral nervous system neoplasm	0.000402	0.000436	CcSEcCtD
Epoprostenol—Flatulence—Doxorubicin—peripheral nervous system neoplasm	0.000402	0.000436	CcSEcCtD
Epoprostenol—Tension—Doxorubicin—peripheral nervous system neoplasm	0.0004	0.000434	CcSEcCtD
Epoprostenol—Nervousness—Doxorubicin—peripheral nervous system neoplasm	0.000396	0.00043	CcSEcCtD
Epoprostenol—Syncope—Epirubicin—peripheral nervous system neoplasm	0.000395	0.000429	CcSEcCtD
Epoprostenol—Back pain—Doxorubicin—peripheral nervous system neoplasm	0.000394	0.000428	CcSEcCtD
Epoprostenol—PTGIS—Disease—PPP3R1—peripheral nervous system neoplasm	0.000394	0.00498	CbGpPWpGaD
Epoprostenol—Muscle spasms—Doxorubicin—peripheral nervous system neoplasm	0.000392	0.000426	CcSEcCtD
Epoprostenol—Palpitations—Epirubicin—peripheral nervous system neoplasm	0.000389	0.000423	CcSEcCtD
Epoprostenol—Loss of consciousness—Epirubicin—peripheral nervous system neoplasm	0.000387	0.00042	CcSEcCtD
Epoprostenol—Cough—Epirubicin—peripheral nervous system neoplasm	0.000384	0.000417	CcSEcCtD
Epoprostenol—PTGIR—Hemostasis—KNG1—peripheral nervous system neoplasm	0.000383	0.00484	CbGpPWpGaD
Epoprostenol—Nausea—Etoposide—peripheral nervous system neoplasm	0.000381	0.000414	CcSEcCtD
Epoprostenol—Anaemia—Doxorubicin—peripheral nervous system neoplasm	0.000377	0.000409	CcSEcCtD
Epoprostenol—Myalgia—Epirubicin—peripheral nervous system neoplasm	0.000375	0.000407	CcSEcCtD
Epoprostenol—Arthralgia—Epirubicin—peripheral nervous system neoplasm	0.000375	0.000407	CcSEcCtD
Epoprostenol—Chest pain—Epirubicin—peripheral nervous system neoplasm	0.000375	0.000407	CcSEcCtD
Epoprostenol—Agitation—Doxorubicin—peripheral nervous system neoplasm	0.000375	0.000407	CcSEcCtD
Epoprostenol—PTGER1—GPCR ligand binding—GNAS—peripheral nervous system neoplasm	0.000374	0.00473	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR ligand binding—GNAS—peripheral nervous system neoplasm	0.000374	0.00473	CbGpPWpGaD
Epoprostenol—Anxiety—Epirubicin—peripheral nervous system neoplasm	0.000374	0.000406	CcSEcCtD
Epoprostenol—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—peripheral nervous system neoplasm	0.000372	0.000404	CcSEcCtD
Epoprostenol—P2RY12—Signaling by GPCR—PPP3R1—peripheral nervous system neoplasm	0.000371	0.0047	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—VIP—peripheral nervous system neoplasm	0.00037	0.00468	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—VIP—peripheral nervous system neoplasm	0.00037	0.00468	CbGpPWpGaD
Epoprostenol—Dry mouth—Epirubicin—peripheral nervous system neoplasm	0.000367	0.000398	CcSEcCtD
Epoprostenol—Syncope—Doxorubicin—peripheral nervous system neoplasm	0.000366	0.000397	CcSEcCtD
Epoprostenol—P2RY12—Hemostasis—GNAS—peripheral nervous system neoplasm	0.000364	0.0046	CbGpPWpGaD
Epoprostenol—Confusional state—Epirubicin—peripheral nervous system neoplasm	0.000362	0.000394	CcSEcCtD
Epoprostenol—Palpitations—Doxorubicin—peripheral nervous system neoplasm	0.00036	0.000391	CcSEcCtD
Epoprostenol—Anaphylactic shock—Epirubicin—peripheral nervous system neoplasm	0.00036	0.00039	CcSEcCtD
Epoprostenol—Oedema—Epirubicin—peripheral nervous system neoplasm	0.00036	0.00039	CcSEcCtD
Epoprostenol—Loss of consciousness—Doxorubicin—peripheral nervous system neoplasm	0.000358	0.000389	CcSEcCtD
Epoprostenol—Infection—Epirubicin—peripheral nervous system neoplasm	0.000357	0.000388	CcSEcCtD
Epoprostenol—Cough—Doxorubicin—peripheral nervous system neoplasm	0.000356	0.000386	CcSEcCtD
Epoprostenol—Shock—Epirubicin—peripheral nervous system neoplasm	0.000354	0.000384	CcSEcCtD
Epoprostenol—Nervous system disorder—Epirubicin—peripheral nervous system neoplasm	0.000353	0.000383	CcSEcCtD
Epoprostenol—Thrombocytopenia—Epirubicin—peripheral nervous system neoplasm	0.000352	0.000382	CcSEcCtD
Epoprostenol—Tachycardia—Epirubicin—peripheral nervous system neoplasm	0.000351	0.000381	CcSEcCtD
Epoprostenol—Skin disorder—Epirubicin—peripheral nervous system neoplasm	0.000349	0.000379	CcSEcCtD
Epoprostenol—Hyperhidrosis—Epirubicin—peripheral nervous system neoplasm	0.000348	0.000377	CcSEcCtD
Epoprostenol—Myalgia—Doxorubicin—peripheral nervous system neoplasm	0.000347	0.000377	CcSEcCtD
Epoprostenol—Arthralgia—Doxorubicin—peripheral nervous system neoplasm	0.000347	0.000377	CcSEcCtD
Epoprostenol—Chest pain—Doxorubicin—peripheral nervous system neoplasm	0.000347	0.000377	CcSEcCtD
Epoprostenol—P2RY12—Hemostasis—HGF—peripheral nervous system neoplasm	0.000346	0.00438	CbGpPWpGaD
Epoprostenol—Anxiety—Doxorubicin—peripheral nervous system neoplasm	0.000346	0.000375	CcSEcCtD
Epoprostenol—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—peripheral nervous system neoplasm	0.000345	0.000374	CcSEcCtD
Epoprostenol—Anorexia—Epirubicin—peripheral nervous system neoplasm	0.000343	0.000372	CcSEcCtD
Epoprostenol—PTGER1—Signaling by GPCR—PPP3R1—peripheral nervous system neoplasm	0.000342	0.00432	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—PPP3R1—peripheral nervous system neoplasm	0.000342	0.00432	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—ENO2—peripheral nervous system neoplasm	0.000341	0.00431	CbGpPWpGaD
Epoprostenol—Dry mouth—Doxorubicin—peripheral nervous system neoplasm	0.000339	0.000369	CcSEcCtD
Epoprostenol—Hypotension—Epirubicin—peripheral nervous system neoplasm	0.000336	0.000365	CcSEcCtD
Epoprostenol—Confusional state—Doxorubicin—peripheral nervous system neoplasm	0.000335	0.000364	CcSEcCtD
Epoprostenol—PTGIR—Hemostasis—GNAS—peripheral nervous system neoplasm	0.000335	0.00423	CbGpPWpGaD
Epoprostenol—Oedema—Doxorubicin—peripheral nervous system neoplasm	0.000333	0.000361	CcSEcCtD
Epoprostenol—Anaphylactic shock—Doxorubicin—peripheral nervous system neoplasm	0.000333	0.000361	CcSEcCtD
Epoprostenol—Infection—Doxorubicin—peripheral nervous system neoplasm	0.00033	0.000359	CcSEcCtD
Epoprostenol—Musculoskeletal discomfort—Epirubicin—peripheral nervous system neoplasm	0.000328	0.000356	CcSEcCtD
Epoprostenol—Shock—Doxorubicin—peripheral nervous system neoplasm	0.000327	0.000355	CcSEcCtD
Epoprostenol—Nervous system disorder—Doxorubicin—peripheral nervous system neoplasm	0.000326	0.000354	CcSEcCtD
Epoprostenol—Thrombocytopenia—Doxorubicin—peripheral nervous system neoplasm	0.000326	0.000354	CcSEcCtD
Epoprostenol—Insomnia—Epirubicin—peripheral nervous system neoplasm	0.000325	0.000353	CcSEcCtD
Epoprostenol—Tachycardia—Doxorubicin—peripheral nervous system neoplasm	0.000325	0.000353	CcSEcCtD
Epoprostenol—Skin disorder—Doxorubicin—peripheral nervous system neoplasm	0.000323	0.000351	CcSEcCtD
Epoprostenol—Paraesthesia—Epirubicin—peripheral nervous system neoplasm	0.000323	0.000351	CcSEcCtD
Epoprostenol—Hyperhidrosis—Doxorubicin—peripheral nervous system neoplasm	0.000322	0.000349	CcSEcCtD
Epoprostenol—Dyspnoea—Epirubicin—peripheral nervous system neoplasm	0.000321	0.000348	CcSEcCtD
Epoprostenol—Somnolence—Epirubicin—peripheral nervous system neoplasm	0.00032	0.000347	CcSEcCtD
Epoprostenol—PTGIR—Hemostasis—HGF—peripheral nervous system neoplasm	0.000319	0.00403	CbGpPWpGaD
Epoprostenol—Anorexia—Doxorubicin—peripheral nervous system neoplasm	0.000317	0.000344	CcSEcCtD
Epoprostenol—Dyspepsia—Epirubicin—peripheral nervous system neoplasm	0.000316	0.000344	CcSEcCtD
Epoprostenol—P2RY12—Signaling Pathways—NTS—peripheral nervous system neoplasm	0.000314	0.00397	CbGpPWpGaD
Epoprostenol—Decreased appetite—Epirubicin—peripheral nervous system neoplasm	0.000313	0.000339	CcSEcCtD
Epoprostenol—Hypotension—Doxorubicin—peripheral nervous system neoplasm	0.000311	0.000338	CcSEcCtD
Epoprostenol—Gastrointestinal disorder—Epirubicin—peripheral nervous system neoplasm	0.00031	0.000337	CcSEcCtD
Epoprostenol—Fatigue—Epirubicin—peripheral nervous system neoplasm	0.00031	0.000337	CcSEcCtD
Epoprostenol—Pain—Epirubicin—peripheral nervous system neoplasm	0.000307	0.000334	CcSEcCtD
Epoprostenol—Constipation—Epirubicin—peripheral nervous system neoplasm	0.000307	0.000334	CcSEcCtD
Epoprostenol—Musculoskeletal discomfort—Doxorubicin—peripheral nervous system neoplasm	0.000303	0.000329	CcSEcCtD
Epoprostenol—Insomnia—Doxorubicin—peripheral nervous system neoplasm	0.000301	0.000327	CcSEcCtD
Epoprostenol—P2RY12—Signaling Pathways—CD55—peripheral nervous system neoplasm	0.000301	0.0038	CbGpPWpGaD
Epoprostenol—Paraesthesia—Doxorubicin—peripheral nervous system neoplasm	0.000299	0.000324	CcSEcCtD
Epoprostenol—Dyspnoea—Doxorubicin—peripheral nervous system neoplasm	0.000297	0.000322	CcSEcCtD
Epoprostenol—Somnolence—Doxorubicin—peripheral nervous system neoplasm	0.000296	0.000321	CcSEcCtD
Epoprostenol—Gastrointestinal pain—Epirubicin—peripheral nervous system neoplasm	0.000294	0.000319	CcSEcCtD
Epoprostenol—Dyspepsia—Doxorubicin—peripheral nervous system neoplasm	0.000293	0.000318	CcSEcCtD
Epoprostenol—Decreased appetite—Doxorubicin—peripheral nervous system neoplasm	0.000289	0.000314	CcSEcCtD
Epoprostenol—PTGIR—Signaling Pathways—NTS—peripheral nervous system neoplasm	0.000289	0.00365	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—NTS—peripheral nervous system neoplasm	0.000289	0.00365	CbGpPWpGaD
Epoprostenol—Gastrointestinal disorder—Doxorubicin—peripheral nervous system neoplasm	0.000287	0.000312	CcSEcCtD
Epoprostenol—Fatigue—Doxorubicin—peripheral nervous system neoplasm	0.000287	0.000311	CcSEcCtD
Epoprostenol—PTGIS—Metabolism—ENO2—peripheral nervous system neoplasm	0.000286	0.00361	CbGpPWpGaD
Epoprostenol—Urticaria—Epirubicin—peripheral nervous system neoplasm	0.000286	0.00031	CcSEcCtD
Epoprostenol—Pain—Doxorubicin—peripheral nervous system neoplasm	0.000284	0.000309	CcSEcCtD
Epoprostenol—Constipation—Doxorubicin—peripheral nervous system neoplasm	0.000284	0.000309	CcSEcCtD
Epoprostenol—Abdominal pain—Epirubicin—peripheral nervous system neoplasm	0.000284	0.000309	CcSEcCtD
Epoprostenol—Body temperature increased—Epirubicin—peripheral nervous system neoplasm	0.000284	0.000309	CcSEcCtD
Epoprostenol—PTGER1—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—peripheral nervous system neoplasm	0.000277	0.00351	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—CD55—peripheral nervous system neoplasm	0.000277	0.0035	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—CD55—peripheral nervous system neoplasm	0.000277	0.0035	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—SLC2A1—peripheral nervous system neoplasm	0.000275	0.00348	CbGpPWpGaD
Epoprostenol—Gastrointestinal pain—Doxorubicin—peripheral nervous system neoplasm	0.000272	0.000295	CcSEcCtD
Epoprostenol—Hypersensitivity—Epirubicin—peripheral nervous system neoplasm	0.000265	0.000288	CcSEcCtD
Epoprostenol—Urticaria—Doxorubicin—peripheral nervous system neoplasm	0.000264	0.000287	CcSEcCtD
Epoprostenol—Body temperature increased—Doxorubicin—peripheral nervous system neoplasm	0.000263	0.000286	CcSEcCtD
Epoprostenol—Abdominal pain—Doxorubicin—peripheral nervous system neoplasm	0.000263	0.000286	CcSEcCtD
Epoprostenol—P2RY12—GPCR downstream signaling—KNG1—peripheral nervous system neoplasm	0.000263	0.00332	CbGpPWpGaD
Epoprostenol—Asthenia—Epirubicin—peripheral nervous system neoplasm	0.000258	0.00028	CcSEcCtD
Epoprostenol—Pruritus—Epirubicin—peripheral nervous system neoplasm	0.000254	0.000276	CcSEcCtD
Epoprostenol—P2RY12—Hemostasis—PTPN11—peripheral nervous system neoplasm	0.000253	0.00319	CbGpPWpGaD
Epoprostenol—Diarrhoea—Epirubicin—peripheral nervous system neoplasm	0.000246	0.000267	CcSEcCtD
Epoprostenol—Hypersensitivity—Doxorubicin—peripheral nervous system neoplasm	0.000245	0.000266	CcSEcCtD
Epoprostenol—PTGIR—GPCR downstream signaling—KNG1—peripheral nervous system neoplasm	0.000242	0.00306	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR downstream signaling—KNG1—peripheral nervous system neoplasm	0.000242	0.00306	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—BCHE—peripheral nervous system neoplasm	0.000241	0.00305	CbGpPWpGaD
Epoprostenol—Asthenia—Doxorubicin—peripheral nervous system neoplasm	0.000239	0.000259	CcSEcCtD
Epoprostenol—P2RY12—Signaling by GPCR—KNG1—peripheral nervous system neoplasm	0.000239	0.00302	CbGpPWpGaD
Epoprostenol—Dizziness—Epirubicin—peripheral nervous system neoplasm	0.000238	0.000258	CcSEcCtD
Epoprostenol—P2RY12—Signaling Pathways—VIP—peripheral nervous system neoplasm	0.000238	0.00301	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—HSD17B12—peripheral nervous system neoplasm	0.000237	0.00299	CbGpPWpGaD
Epoprostenol—Pruritus—Doxorubicin—peripheral nervous system neoplasm	0.000235	0.000256	CcSEcCtD
Epoprostenol—PTGIR—Hemostasis—PTPN11—peripheral nervous system neoplasm	0.000233	0.00294	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—SLC2A1—peripheral nervous system neoplasm	0.00023	0.00291	CbGpPWpGaD
Epoprostenol—P2RY12—GPCR downstream signaling—GNAS—peripheral nervous system neoplasm	0.00023	0.00291	CbGpPWpGaD
Epoprostenol—Vomiting—Epirubicin—peripheral nervous system neoplasm	0.000229	0.000248	CcSEcCtD
Epoprostenol—Diarrhoea—Doxorubicin—peripheral nervous system neoplasm	0.000228	0.000247	CcSEcCtD
Epoprostenol—PTGIS—Metabolism—TH—peripheral nervous system neoplasm	0.000227	0.00287	CbGpPWpGaD
Epoprostenol—Rash—Epirubicin—peripheral nervous system neoplasm	0.000227	0.000246	CcSEcCtD
Epoprostenol—Dermatitis—Epirubicin—peripheral nervous system neoplasm	0.000226	0.000246	CcSEcCtD
Epoprostenol—Headache—Epirubicin—peripheral nervous system neoplasm	0.000225	0.000245	CcSEcCtD
Epoprostenol—Dizziness—Doxorubicin—peripheral nervous system neoplasm	0.00022	0.000239	CcSEcCtD
Epoprostenol—PTGER1—Signaling by GPCR—KNG1—peripheral nervous system neoplasm	0.00022	0.00278	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—KNG1—peripheral nervous system neoplasm	0.00022	0.00278	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	0.000219	0.00277	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—VIP—peripheral nervous system neoplasm	0.000219	0.00277	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—VIP—peripheral nervous system neoplasm	0.000219	0.00277	CbGpPWpGaD
Epoprostenol—Nausea—Epirubicin—peripheral nervous system neoplasm	0.000214	0.000232	CcSEcCtD
Epoprostenol—Vomiting—Doxorubicin—peripheral nervous system neoplasm	0.000212	0.00023	CcSEcCtD
Epoprostenol—PTGER1—GPCR downstream signaling—GNAS—peripheral nervous system neoplasm	0.000211	0.00267	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR downstream signaling—GNAS—peripheral nervous system neoplasm	0.000211	0.00267	CbGpPWpGaD
Epoprostenol—Rash—Doxorubicin—peripheral nervous system neoplasm	0.00021	0.000228	CcSEcCtD
Epoprostenol—Dermatitis—Doxorubicin—peripheral nervous system neoplasm	0.00021	0.000228	CcSEcCtD
Epoprostenol—P2RY12—Signaling by GPCR—GNAS—peripheral nervous system neoplasm	0.000209	0.00264	CbGpPWpGaD
Epoprostenol—Headache—Doxorubicin—peripheral nervous system neoplasm	0.000208	0.000226	CcSEcCtD
Epoprostenol—PTGER1—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—peripheral nervous system neoplasm	0.000203	0.00256	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	0.000202	0.00255	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	0.000202	0.00255	CbGpPWpGaD
Epoprostenol—Nausea—Doxorubicin—peripheral nervous system neoplasm	0.000198	0.000215	CcSEcCtD
Epoprostenol—PTGIR—Signaling by GPCR—GNAS—peripheral nervous system neoplasm	0.000192	0.00243	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—GNAS—peripheral nervous system neoplasm	0.000192	0.00243	CbGpPWpGaD
Epoprostenol—P2RY12—Platelet activation, signaling and aggregation—AKT1—peripheral nervous system neoplasm	0.00019	0.00241	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—GNAS—peripheral nervous system neoplasm	0.000185	0.00234	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—ABCB1—peripheral nervous system neoplasm	0.000182	0.0023	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	0.000165	0.00208	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—PPIP5K2—peripheral nervous system neoplasm	0.000156	0.00197	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—PTPN11—peripheral nervous system neoplasm	0.000154	0.00194	CbGpPWpGaD
Epoprostenol—P2RY12—Hemostasis—NRAS—peripheral nervous system neoplasm	0.000152	0.00192	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	0.000152	0.00192	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	0.000152	0.00192	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—PTPN11—peripheral nervous system neoplasm	0.000145	0.00183	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—KNG1—peripheral nervous system neoplasm	0.000141	0.00178	CbGpPWpGaD
Epoprostenol—PTGIR—Hemostasis—NRAS—peripheral nervous system neoplasm	0.00014	0.00177	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	0.000134	0.0017	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—PTPN11—peripheral nervous system neoplasm	0.000133	0.00169	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—PTPN11—peripheral nervous system neoplasm	0.000133	0.00169	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—KNG1—peripheral nervous system neoplasm	0.00013	0.00164	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—KNG1—peripheral nervous system neoplasm	0.00013	0.00164	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	0.000124	0.00156	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	0.000124	0.00156	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—GNAS—peripheral nervous system neoplasm	0.000123	0.00156	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—ERBB2—peripheral nervous system neoplasm	0.000122	0.00154	CbGpPWpGaD
Epoprostenol—P2RY12—Hemostasis—TP53—peripheral nervous system neoplasm	0.000116	0.00147	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—GNAS—peripheral nervous system neoplasm	0.000113	0.00143	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—GNAS—peripheral nervous system neoplasm	0.000113	0.00143	CbGpPWpGaD
Epoprostenol—P2RY12—Hemostasis—HRAS—peripheral nervous system neoplasm	0.000111	0.00141	CbGpPWpGaD
Epoprostenol—PTGIR—Hemostasis—TP53—peripheral nervous system neoplasm	0.000107	0.00135	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—HSD17B12—peripheral nervous system neoplasm	0.000105	0.00133	CbGpPWpGaD
Epoprostenol—PTGIR—Hemostasis—HRAS—peripheral nervous system neoplasm	0.000102	0.00129	CbGpPWpGaD
Epoprostenol—P2RY12—Hemostasis—AKT1—peripheral nervous system neoplasm	9.81e-05	0.00124	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—NRAS—peripheral nervous system neoplasm	9.25e-05	0.00117	CbGpPWpGaD
Epoprostenol—PTGIR—Hemostasis—AKT1—peripheral nervous system neoplasm	9.03e-05	0.00114	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—BCHE—peripheral nervous system neoplasm	8.76e-05	0.00111	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	8.72e-05	0.0011	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—MYC—peripheral nervous system neoplasm	8.61e-05	0.00109	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	8.57e-05	0.00108	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	8.02e-05	0.00101	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	8.02e-05	0.00101	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	7.88e-05	0.000997	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	7.88e-05	0.000997	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—GNS—peripheral nervous system neoplasm	7.62e-05	0.000964	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—NME1—peripheral nervous system neoplasm	7.31e-05	0.000924	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—COX2—peripheral nervous system neoplasm	7.03e-05	0.000889	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	6.77e-05	0.000856	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—HRAS—peripheral nervous system neoplasm	6.76e-05	0.000855	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	6.38e-05	0.000807	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	6.23e-05	0.000788	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	6.23e-05	0.000788	CbGpPWpGaD
Epoprostenol—P2RY12—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	6.2e-05	0.000784	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—CASP3—peripheral nervous system neoplasm	6.14e-05	0.000777	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—AKT1—peripheral nervous system neoplasm	5.97e-05	0.000755	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	5.87e-05	0.000742	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	5.87e-05	0.000742	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	5.71e-05	0.000722	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	5.71e-05	0.000722	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—CASP3—peripheral nervous system neoplasm	5.65e-05	0.000715	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—CASP3—peripheral nervous system neoplasm	5.65e-05	0.000715	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	5.63e-05	0.000712	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	5.18e-05	0.000655	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	5.18e-05	0.000655	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—NRAS—peripheral nervous system neoplasm	5.15e-05	0.000651	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—AKT1—peripheral nervous system neoplasm	5e-05	0.000633	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—MYC—peripheral nervous system neoplasm	4.8e-05	0.000607	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—NRAS—peripheral nervous system neoplasm	4.74e-05	0.000599	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—NRAS—peripheral nervous system neoplasm	4.74e-05	0.000599	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—ENO2—peripheral nervous system neoplasm	4.62e-05	0.000584	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—MYC—peripheral nervous system neoplasm	4.41e-05	0.000558	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—MYC—peripheral nervous system neoplasm	4.41e-05	0.000558	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—TP53—peripheral nervous system neoplasm	3.94e-05	0.000498	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—BCHE—peripheral nervous system neoplasm	3.9e-05	0.000493	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—HRAS—peripheral nervous system neoplasm	3.77e-05	0.000476	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—SLC2A1—peripheral nervous system neoplasm	3.72e-05	0.000471	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—TH—peripheral nervous system neoplasm	3.67e-05	0.000464	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—TP53—peripheral nervous system neoplasm	3.63e-05	0.000458	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—TP53—peripheral nervous system neoplasm	3.63e-05	0.000458	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—HRAS—peripheral nervous system neoplasm	3.47e-05	0.000438	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—HRAS—peripheral nervous system neoplasm	3.47e-05	0.000438	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—AKT1—peripheral nervous system neoplasm	3.33e-05	0.000421	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—AKT1—peripheral nervous system neoplasm	3.06e-05	0.000387	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—AKT1—peripheral nervous system neoplasm	3.06e-05	0.000387	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—GNAS—peripheral nervous system neoplasm	2.99e-05	0.000379	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—ABCB1—peripheral nervous system neoplasm	2.94e-05	0.000372	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—AKT1—peripheral nervous system neoplasm	8.08e-06	0.000102	CbGpPWpGaD
